Selective TrkA Agonists for Retinal Ganglion Cell Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly open angle glaucoma, are ineffective in halting progressive retinal ganglion cell (RGC) apoptosis and visual field loss despite normalizing intraocular pressure, due to the complex and often opposite functions of neurotrophin receptors, making it difficult to predict in vivo pharmacology and manufacture recombinant NTF polypeptides are costly and challenging to produce.
Innovation Solution
The use of selective TrkA receptor agonists, such as β-turn peptidomimetic cyclic compounds, and p75 receptor antagonists, administered with intraocular pressure-normalizing drugs like betaxolol, to modulate neurotrophin receptor activity and provide trophic support to RGCs, thereby preventing apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant NTF polypeptides are used to treat glaucoma, then trophic support for RGCs is provided, but manufacturing difficulty and cost increase
Solution Approach 1:
The patent uses small molecule compounds that copy the biological activity of complex recombinant neurotrophin polypeptides. These small molecules mimic the trophic support effects of NTFs without requiring complex protein synthesis, purification, and formulation processes, thereby dramatically simplifying manufacturing while maintaining therapeutic effectiveness.
Solution Approach 2:
The invention employs stable small molecule compounds that can be synthesized through straightforward chemical processes rather than expensive biotechnological methods. These small molecules offer a cost-effective alternative to recombinant proteins, enabling scalable production and broader accessibility for glaucoma treatment.
2Reliability
If recombinant NTF polypeptides are used to treat glaucoma, then trophic support for RGCs is provided, but production cost increases
Solution Approach 1:
The patent uses small molecule compounds that copy the biological activity of complex recombinant neurotrophin polypeptides. These small molecules mimic the trophic support effects of NTFs without requiring complex protein synthesis, purification, and formulation processes, thereby dramatically simplifying manufacturing while maintaining therapeutic effectiveness.
Solution Approach 2:
The invention employs stable small molecule compounds that can be synthesized through straightforward chemical processes rather than expensive biotechnological methods. These small molecules offer a cost-effective alternative to recombinant proteins, enabling scalable production and broader accessibility for glaucoma treatment.
3Reliability
If Trk and p75 receptor ligands are used, then RGC survival signals are activated, but complex opposite functions and multiple pathways make in vivo pharmacology unpredictable
Solution Approach 1:
The patent employs selective TrkA receptor agonists that specifically target the pro-survival TrkA pathway without activating the p75 receptor. This segmentation of receptor targeting isolates the beneficial survival signals from the harmful apoptotic signals, creating a predictable and controllable pharmacological profile with clear mechanism of action.
Solution Approach 2:
Instead of using promiscuous ligands that activate both Trk and p75 receptors, the invention inverts the approach by using highly selective TrkA agonists that exclusively activate the desired survival pathway. This selective activation strategy reverses the traditional approach of using broad-spectrum neurotrophins, thereby simplifying the pharmacological profile and improving predictability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces RGC loss and halts glaucoma progression by specifically targeting Trk receptors and p75 receptors, offering a stable and effective treatment option that complements intraocular pressure normalization.
Implementation Method 1
Trk family receptors mediating signal transduction associated with 'positive' signals of cell survival and differentiation
Implementation Method 2
The p75 receptor is bound non-selectively by all NTFs, making its activation quite promiscuous
Data Source
Figure 1A~1C
Figure 1D
Figure 2
AI summary
The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise ß-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma.